# 4DMT | Powering The Future Of Genetic Medicines

> Markdown mirror of DialtoneApp's public top-site detail page for `4dmoleculartherapeutics.com`.

URL: https://dialtoneapp.com/top-sites/4dmoleculartherapeutics.com/index.md
Canonical HTML: https://dialtoneapp.com/top-sites/4dmoleculartherapeutics.com

## Summary

- Domain: `4dmoleculartherapeutics.com`
- Website: https://4dmoleculartherapeutics.com
- Description: ai readable | score 20 | purchase read only
- Label: ai_readable
- Payment surface: Not available
- Purchase boundary: read_only
- Control boundary: unknown
- Rank: 716437

## robots

~~~text
User-agent: *
Disallow: /wp-admin/
Allow: /wp-admin/admin-ajax.php

Sitemap: https://4dmoleculartherapeutics.com/sitemap.xml
Sitemap: https://4dmoleculartherapeutics.com/sitemap.rss
~~~

## llms

~~~text
Generated by All in One SEO v4.9.5.1, this is an llms.txt file, used by LLMs to index the site.

# 4DMT

Powering The Future Of Genetic Medicines

## Sitemaps

- [XML Sitemap](https://4dmoleculartherapeutics.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [The Onyx Life Sciences Report: Companies we're watching in 2026](https://online.fliphtml5.com/vfvls/Onyx_Life_Sciences_Fortune/#p=2#new_tab)
- [Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation](https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2026-hold-for-biopharma-part-4-rd-innovation-NDREFKFVB5DZPAQLA5CIZHE7OI/#new_tab)
- [4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD](https://www.retinalphysician.com/news/2026/4dmt-completes-enrollment-in-wet-amd-trial/#new_tab)
- [4DMT Completes Enrollment for Phase 3 Trial of 4D-150 for Wet AMD](https://eyewire.news/news/4dmt-completes-enrollment-for-4d-150-clinical-trial?c4src=article:infinite-scroll#new_tab)
- [The gene therapy shift: A closer look at the science powering next-generation retinal treatments](https://www.modernretina.com/view/the-gene-therapy-shift-a-closer-look-at-the-science-powering-next-generation-retinal-treatments#new_tab)
- ["Speed is survival": Inside 4D Molecular Therapeutics bid to scale genetic medicine](https://www.onyxnewsroom.com/speed-is-survival-inside-4d-molecular-therapeutics-bid-to-scale-genetic-medicine/#new_tab)
- [4DMT Company Updates](https://eyewire.news/tv/4dmt-aao-2025#new_tab)
- [4D-150 maintains visual acuity in wet AMD at 2 years](https://www.healio.com/news/ophthalmology/20251112/4d150-maintains-visual-acuity-in-wet-amd-at-2-years#new_tab)
- [4DMT eyes $420M deal from Otsuka, with cash aimed at retinal gene therapy's phase 3 plans](https://www.fiercebiotech.com/biotech/4dmt-eyes-385m-deal-otsuka-cash-aimed-retinal-gene-therapys-phase-3-plans#new_tab)
- [CF Foundation adds to investment in 4DMT's CF gene therapy](https://cysticfibrosisnewstoday.com/news/cf-foundation-adds-investment-4dmts-cf-gene-therapy/#new_tab)
- [4DMT's eye gene therapy cuts need for injections that treat diabetic macular edema](https://endpoints.news/4dmts-eye-gene-therapy-cuts-need-for-injections-that-treat-diabetic-macular-edema/#new_tab)
- [A new approach to DME treatment](https://www.healthcentral.com/news/diabetic-macular-edema/new-approach-to-dme-treatment#new_tab)
- [ARVO 2025: Christine Kay, MD, shares interim results from the PRISM trial population extension cohort](https://www.modernretina.com/view/arvo-2025-christine-kay-md-shares-interim-results-from-the-prism-trial-population-extension-cohort#new_tab)
- [FDA grants RMAT designation to 4DMT for DME gene therapy](https://glance.eyesoneyecare.com/stories/2025-05-05/fda-grants-rmat-designation-to-4dmt-for-dme-gene-therapy/#new_tab)
- [First Patients Enrolled in 4DMT's Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD](https://eyewire.news/news/first-patients-enrolled-in-4dmts-phase-3-clinical-trial-evaluating-4d-150-in-wet-amd?c4src=article:infinite-scroll#new_tab)
- [4DMT announces positive 52-week data from phase 2b cohort of PRISM wet AMD study](https://www.ophthalmologytimes.com/view/4dmt-announces-positive-52-week-data-from-phase-2b-cohort-of-prism-wet-amd-study#new_tab)
- [4D-150 Reduces Injection Burden in DME, Paving Way for FDA-Backed Phase 3](https://www.hcplive.com/view/4d-150-reduces-injection-burden-in-dme-paving-way-for-fda-backed-phase-3#new_tab)
- [Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends](https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2025-hold-for-biopharma-part-5-clinical-trials-trends-HRPZAHMMXJEL5GVYSK664HNA5I/)
- [The Multifaceted Future of Pharma – Chapter 5: Betting on Biopharma and Better Bioprocessing](https://themedicinemaker.com/campaign-pages/the-multifaceted-future-of-pharma-chapter-5-betting-on-biopharma-and-better-bioprocessing?utm_campaign=the multifaceted future of pharma&utm_source=landingpage&utm_medium=cpc#new_tab)
- [Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry](https://insights.citeline.com/scrip/scrip-asks/scrip-asks-what-does-2025-hold-for-biopharma-part-1-the-state-of-the-biopharma-industry-RDAWZN4PR5CNLOWN234JZ6ZM3I/#new_tab)
- [4D-150 for DME moving to phase 3 trial following positive interim data](https://www.healio.com/news/ophthalmology/20250113/4d150-for-dme-moving-to-phase-3-trial-following-positive-interim-data#new_tab)
- [Leveraging Directed Evolution To Optimize AAV Vector Design](https://www.cellandgene.com/doc/leveraging-directed-evolution-to-optimize-aav-vector-design-0001#new_tab)
- [VIDEO: Intravitreally administered 4D-150 shows 90% reduction in wet AMD treatment burden](https://www.healio.com/news/ophthalmology/20241010/video-intravitreally-administered-4d150-shows-90-reduction-in-wet-amd-treatment-burden#new_tab)
- [David Kirn, Co-Founder & CEO, named a 2024 PharmaVoice 100 honoree in the Standout Leaders category](https://www.pharmavoice.com/news/pv100-pharma-leaders-executives/726233/#dr-david-kirn#new_tab)
- [Fresh data intensifies race for a major gene therapy target](https://www.pharmavoice.com/news/gene-therapy-amd-4d-molecular-abbvie-regenxbio/727942/#new_tab)
- [4DMT's gene therapy reduced need for standard-of-care injections to treat age-associated vision loss](https://endpts.com/4dmts-gene-therapy-reduced-need-for-standard-of-care-injections-to-treat-age-associated-vision-loss/#new_tab)
- [In race to make gene therapy for age-related blindness, 4D Molecular announces positive results](https://www.statnews.com/2024/09/18/macular-degeneration-gene-therapy-4d-molecular/#new_tab)
- [East Bay biotech targeting eye diseases makes 3 critical hires](https://www.bizjournals.com/sanfrancisco/news/2024/08/05/ophthalmology-wet-amd-4d-molecular-therapeutics.html#new_tab)
- [4D Molecular Therapeutics’ Wet AMD Gene Therapy 4D-150 Reduces Need for antiVEGF Injections](https://www.cgtlive.com/view/4d-molecular-therapeutics-wet-amd-gene-therapy-4d-150-reduces-antivegf-injections#new_tab)
- [4D Molecular Therapeutics announces positive initial interim 24-week landmark data from population extension cohort of PRISM phase 2 clinical trial of 4D-150](https://www.ophthalmologytimes.com/view/4d-molecular-therapeutics-announces-positive-initial-interim-24-week-landmark-data-from-population-extension-cohort-of-prism-phase-2-clinical-trial-of-4d-150#new_tab)
- [VIDEO: Jennifer Taylor-Cousar, MD, MSCS, discusses 4D-710, 4DMT’s gene therapy candidate for treating cystic fibrosis](https://www.cgtlive.com/view/taylor-cousar-early-efficacy-cystic-fibrosis-gene-therapy#new_tab)
- [VIDEO: David Kirn, Co-Founder & CEO, 4DMT, provides an update on two candidates for retinal diseases](https://www.healio.com/news/ophthalmology/20240701/video-4d-molecular-therapeutics-shares-update-on-retinal-disease-candidates#new_tab)
- [The Origins of Oncolytic Viral Therapy](https://viewonline.drugdiscoverynews.com/hubfs/DDN/DDN  Digital Edition /July 2024/DDN July 2024 Issue.pdf#page=12#new_tab)
- [Q&A with David Kirn, Co-Founder & CEO, 4DMT](https://www.investmentreports.co/interview/david-kirn-1084#new_tab)
- [VIDEO: ‘Excellent’ anatomic, vision control seen with 4D-150 at 24 weeks](https://www.healio.com/news/ophthalmology/20240617/video-excellent-anatomic-vision-control-seen-with-4d150-at-24-weeks#new_tab)
- [Uneek Mehra speaks on a licensing and deal-making panel at BIO 2024](https://www.linkedin.com/feed/update/urn:li:activity:7204120467253710848#new_tab)
- [Using Directed Evolution to Develop New Vectors for Genetic Medicines](https://art19.com/shows/rarecast/episodes/44a116d0-da9f-48c9-b610-0375250cd7a6#new_tab)
- [Using Directed Evolution to Develop New Vectors for Genetic Medicines](https://art19.com/shows/rarecast/episodes/44a116d0-da9f-48c9-b610-0375250cd7a6#new_tab)
- [Vectorized biologics: are patients and payers ready to swap biologics for gene therapies?](https://www.biocentury.com/article/651737/vectorized-biologics-are-patients-and-payers-ready-to-swap-biologics-for-gene-therapies#new_tab)
- [4D Molecular soars as mid-stage data for eye disease therapy 'checks all boxes'](https://www.reuters.com/markets/us/4d-molecular-soars-mid-stage-data-eye-disease-therapy-checks-all-boxes-2024-02-05/#new_tab)
- [Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology](https://scrip.citeline.com/SC149709/Scrip-AsksWhat-Does-2024-Hold-For-Biopharma-Part-4-Transformative-Technology?utm_content=280370836#new_tab)
- [Navigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT](https://www.biotech2050.com/episodes/navigating-platform-vs-product-tension-david-kirn-co-founder-amp-ceo-4dmt#new_tab)
- [One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery](https://www.pharmavoice.com/news/4dmt-gene-therapy-drug-delivery/704155/#new_tab)
- [4D Molecular Therapeutics' gene therapy cuts Eylea use in wet AMD patients, biotech divulges plans for pivotal studies](https://endpts.com/4d-molecular-therapeutics-gene-therapy-cuts-eylea-use-in-wet-amd-patients-biotech-divulges-plans-for-pivotal-studies/#new_tab)
- [4DMT links gene therapy to drop in Eylea injections, fueling plans to enter phase 3](https://www.fiercebiotech.com/biotech/4dmt-links-gene-therapy-drop-eylea-injections-fueling-plans-enter-phase-3#new_tab)
- [4DMT shares pipeline progress and the appointment of new CSO and SAB board members](https://www.modernretina.com/view/4dmt-shares-pipeline-progress-and-the-appointment-of-new-cso-and-sab-board-members#new_tab)
- [Positive Clinical Trial Results and Future Prospects Reinforce Buy Rating for 4D Molecular Therapeutics: An Analysis by Geulah Livshits](https://markets.businessinsider.com/news/stocks/positive-clinical-trial-results-and-future-prospects-reinforce-buy-rating-for-4d-molecular-therapeutics-an-analysis-by-geulah-livshits-1032770554#new_tab)
- [4DMT: First patient enrolled in 4D-150 Phase 2 SPECTRA, PRIS clinical trials](https://www.ophthalmologytimes.com/view/4dmt-first-patient-enrolled-in-4d-150-phase-2-spectra-pris-clinical-trials#new_tab)
- [4DMT and Arbor Biotechnologies Partnership to Develop Genetic Medicines for CNS Diseases](https://www.americanpharmaceuticalreview.com/1315-News/609906-4DMT-and-Arbor-Biotechnologies-Partnership-to-Develop-Genetic-Medicines-for-CNS-Diseases/#new_tab)
- [J&J’s new partnership with Elektrofi; Enyo raises €39M; Arrowhead's $450M offering](https://endpts.com/j-enyo-raises-e39m-arrowheads-450m-offering/#new_tab)
- [4D-710 leads to quality of life gains for CF patients in clinical trial](https://cysticfibrosisnewstoday.com/news/cf-patients-see-quality-life-gains-with-4d-710-gene-therapy-trial/#new_tab)
- [Uneek Mehra speaks on next-gen AAV panel at Chardan's 7th Annual Genetic Medicines Conference](https://www.linkedin.com/posts/4d-molecular-therapeutics-llc_chardangmconf-cgmc2023-geneticmedicines-activity-7115376593501392896-sa4z/#new_tab)
- [Robert Kim receives “Summit of Excellence” Lifetime Achievement Award at the 2023 Clinical Trials at the Summit](https://www.linkedin.com/posts/4d-molecular-therapeutics-llc_cts2023-activity-7075117787165138944-1WhJ/#new_tab)
- [The Medicine Maker Power List 2022](https://themedicinemaker.com/awards/power-list/2022/advanced-medicine/david-kirn#new_tab)
- [On the Field and in the Office, 4DMT CEO David Kirn is a Solid Central Midfielder](https://www.healthleadersmedia.com/pharma/field-and-office-4dmt-ceo-david-kirn-solid-central-midfielder#new_tab)
- [Scrip Asks…What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering](https://scrip.citeline.com/SC147621/Scrip-AsksWhat-Does-2023-Hold-For-Biopharma-Part-2-MA-And-Partnering#new_tab)
- [The Bioverge Podcast: Unlocking the Potential of Genetic Medicines](https://bioverge.com/blog/the-bioverge-podcast-unlocking-the-potential-of-genetic-medicines#new_tab)
- [The Evolution Of Gene Therapy: From Small Market Diseases To Broad Patient Populations](https://www.cellandgene.com/doc/the-evolution-of-gene-therapy-from-small-market-diseases-to-broad-patient-populations-0001#new_tab)
- [What’s one thing Bay Area needs for biotech? CEOs let us know](https://www.bizjournals.com/sanfrancisco/news/2023/06/08/biotech-bay-area-ceos-housing-workforce-bio2023.html#new_tab)
- [Astellas eyes rare ophthalmology, licensing 4DMT's viral vector for gene therapy for up to $962M](https://endpts.com/astellas-licenses-aav-vector-from-4dmt-for-rare-eye-disease-gene-therapy/#new_tab)
- [#NACFC2022 – 4D-710 Safe, Restores CFTR Lung Production in 3 Patients](https://cysticfibrosisnewstoday.com/news/nacfc2022-gene-therapy-4d-710-restores-cftr-production/#new_tab)
- [They were the 10% left out of life-changing treatments. Now these cystic fibrosis patients may finally get help](https://www.statnews.com/2023/02/03/cystic-fibrosis-new-treatments/#new_tab)
- [4D Molecular Therapeutics acquires eye disease asset from Fortress Biotech subsidiary](https://endpts.com/4d-molecular-therapeutics-acquires-asset-from-fortress-biotech-subsidiary/#new_tab)
- [5 Gene Therapy Companies That May Transform the Medical Industry](https://www.nasdaq.com/articles/5-gene-therapy-companies-that-may-transform-the-medical-industry#new_tab)
- [ReCode, Vertex and 4DMT Seek to Help Untreated Cystic Fibrosis Patients](https://www.biospace.com/article/recode-vertex-and-4dmt-seek-to-help-yet-untreated-cystic-fibrosis-patients-/#new_tab)
- [Aerow hits the mark for 4D Molecular](https://www.evaluate.com/vantage/articles/news/trial-results/aerow-hits-mark-4d-molecular#new_tab)
- [4DMT's inhalable gene therapy for cystic fibrosis shows early positive signs in tiny group of patients](https://endpts.com/4dmts-inhalable-gene-therapy-for-cystic-fibrosis-shows-early-positive-signs-in-tiny-group-of-patients/#new_tab)
- [Astellas paves backloaded biobucks deal to test 4DMT's eye disease gene therapy vector](https://www.fiercebiotech.com/biotech/astellas-paves-back-loaded-biobucks-deal-4dmt-test-eye-disease-gene-therapy-vector#new_tab)

## Pages

- [Home](https://4dmoleculartherapeutics.com/) - 4D Molecular Therapeutics designs, develops and commercializes transformative gene therapeutic products for serious unmet medical conditions.
- [About](https://4dmoleculartherapeutics.com/about/) - 4DMT is a clinical stage biopharma company inventing and developing innovative products to unlock the full potential of genetic medicine to treat large market diseases.
- [Pipeline](https://4dmoleculartherapeutics.com/pipeline/) - Our diversified product pipeline spans three therapeutic areas, each of which leverages a unique and proprietary customized vector invented at 4DMT.
- [Contact](https://4dmoleculartherapeutics.com/contact/) - We welcome inquiries regarding products, partnerships and career openings. Contact 4DMT today.
- [Careers](https://4dmoleculartherapeutics.com/careers/) - Our people are the essence of our inspiring, innovative and collaborative environment that encourages individual contributions and provides opportunities for career development.
- [Retinal Diseases](https://4dmoleculartherapeutics.com/patients/retinal-diseases/)
- [Patients](https://4dmoleculartherapeutics.com/patients/)
- [Technology](https://4dmoleculartherapeutics.com/technology/)
- [Cookie Notice](https://4dmoleculartherapeutics.com/cookie-notice/)
- [Footer](https://4dmoleculartherapeutics.com/footer/)
- [General Privacy Notice for individuals in the EU and UK](https://4dmoleculartherapeutics.com/privacy-notice-eu-uk/)
- [Privacy Policy for Non-EU and Non-UK Individuals](https://4dmoleculartherapeutics.com/privacy-notice-row/)
- [Privacy Notice](https://4dmoleculartherapeutics.com/privacy-notice/)
- [Pulmonary Diseases](https://4dmoleculartherapeutics.com/patients/pulmonary-diseases/)
- [Terms of Service](https://4dmoleculartherapeutics.com/terms-of-service/)
- [Investors](https://4dmoleculartherapeutics.com/investors/)
- [Compassionate Use Policy](https://4dmoleculartherapeutics.com/compassionate-use-policy/)

## Team

- [Prof. Sobha Sivaprasad DM, FRCS, FRCOphth](https://4dmoleculartherapeutics.com/team/prof-sobha-sivaprasad-dm-frcs-frcophth/)
- [Kim Maplestone](https://4dmoleculartherapeutics.com/team/kim-maplestone/)
- [An Song, PhD](https://4dmoleculartherapeutics.com/team/an-song-phd/)
- [Calvin W. Roberts, MD](https://4dmoleculartherapeutics.com/team/calvin-w-roberts-md/)
- [Noriyuki Kasahara, MD, PhD](https://4dmoleculartherapeutics.com/team/noriyuki-kasahara-md-phd/)
- [Fred Kamal, PhD](https://4dmoleculartherapeutics.com/team/fred-kamal-phd/)
- [Wiley A. Chambers, MD](https://4dmoleculartherapeutics.com/team/wiley-a-chambers-md/)
- [David Kirn, MD](https://4dmoleculartherapeutics.com/team/david-kirn-md-board/)
- [David Kirn, MD](https://4dmoleculartherapeutics.com/team/david-kirn-md/)
- [Susannah Gray, MBA](https://4dmoleculartherapeutics.com/team/susannah-gray-mba/)
- [Nancy Miller-Rich](https://4dmoleculartherapeutics.com/team/nancy-miller-rich/)
- [Glenn P. Sblendorio](https://4dmoleculartherapeutics.com/team/glenn-p-sblendorio/)
- [Shawn Tomasello, MBA](https://4dmoleculartherapeutics.com/team/shawn-tomasello-mba/)
- [Charles Theuer, MD, PhD](https://4dmoleculartherapeutics.com/team/charles-theuer-m-d-ph-d/)
- [Jacob Chacko, MD, MBA](https://4dmoleculartherapeutics.com/team/jacob-chacko-md-mba/)
- [John F. Milligan, PhD](https://4dmoleculartherapeutics.com/team/john-f-milligan-phd/)
- [Scott Bizily, JD, PhD](https://4dmoleculartherapeutics.com/team/scott-bizily-jd-phd/)
- [Theresa Janke](https://4dmoleculartherapeutics.com/team/theresa-janke/)
- [Kristian Humer](https://4dmoleculartherapeutics.com/team/kristian-humer/)
- [Chris Simms](https://4dmoleculartherapeutics.com/team/chris-simms/)
- [Dhaval Desai, PharmD](https://4dmoleculartherapeutics.com/team/dhaval-desai-pharmd/)
- [Julie Clark, MD](https://4dmoleculartherapeutics.com/team/julie-clark-md/)
- [Katy Barglow, PhD](https://4dmoleculartherapeutics.com/team/katy-barglow-phd/)
- [Yuichiro Ogura, MD, PhD](https://4dmoleculartherapeutics.com/team/yuichiro-ogura-md-phd/)
- [Arshad M. Khanani, MD, MA, FASRS](https://4dmoleculartherapeutics.com/team/arshad-m-khanani-md-ma-fasrs/)
- [Patricio G. Schlottmann, MD](https://4dmoleculartherapeutics.com/team/patricio-g-schlottmann-md/)
- [Dante Pieramici, MD](https://4dmoleculartherapeutics.com/team/dante-pieramici-md/)
- [Anat Loewenstein, MD, MHA](https://4dmoleculartherapeutics.com/team/anat-loewenstein-md-mha/)
- [Frank G. Holz, MD, FEBO, FARVO](https://4dmoleculartherapeutics.com/team/frank-g-holz-md-febo-farvo/)
- [Prof. Gemmy Cheung](https://4dmoleculartherapeutics.com/team/gemmy-cheung/)
- [David S. Boyer, MD](https://4dmoleculartherapeutics.com/team/david-s-boyer-md/)
- [John P. Atkinson, MD](https://4dmoleculartherapeutics.com/team/john-p-atkinson-md/)
- [Douglas Hanahan, PhD](https://4dmoleculartherapeutics.com/team/douglas-hanahan-phd/)
- [Ronald Crystal, MD](https://4dmoleculartherapeutics.com/team/ronald-crystal/)
- [Napoleone Ferrara, MD](https://4dmoleculartherapeutics.com/team/napoleone-ferrara-md/)
- [Paul Utz, MD](https://4dmoleculartherapeutics.com/team/paul-utz/)
- [Amy Rosenberg, MD](https://4dmoleculartherapeutics.com/team/amy-rosenberg/)
- [Richard Moss, MD](https://4dmoleculartherapeutics.com/team/richard-moss/)
- [Amit Gaggar, MD, PhD](https://4dmoleculartherapeutics.com/team/amit-gaggar/)
- [Wenchao Song, PhD](https://4dmoleculartherapeutics.com/team/wenchao-song-phd/)

## Publications

- [AAV mediated gene therapy for cystic fibrosis: Interim results from a Phase 1/2 clinical trial](https://4dmoleculartherapeutics.com/publications/aav-mediated-gene-therapy-for-cystic-fibrosis-interim-results-from-a-phase-1-2-clinical-trial/)
- [Phase 2b Population Extension Cohort Evaluating 4D-150 in Neovascular Age-Related Macular Degeneration: 52-Week Results](https://4dmoleculartherapeutics.com/publications/angiogenesis-exudation-and-degeneration-2025/)
- [Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema](https://4dmoleculartherapeutics.com/publications/interim-results-from-the-spectra-phase-2a-clinical-trial-evaluating-intravitreal-4d-150-in-adults-with-diabetic-macular-edema/)
- [Non-clinical Evaluation of 4D-310 in Combination With Rituximab/Sirolimus: A Translational Study to Support Adoption of a Novel Prophylactic Immunomodulation Regimen in Clinical Trials in Adults with Fabry Disease (Poster)](https://4dmoleculartherapeutics.com/publications/non-clinical-evaluation-of-4d-310-in-combination-with-rituximab-sirolimus-a-translational-study-to-support-adoption-of-a-novel-prophylactic-immunomodulation-regimen-in-clinical-trials-in-adults-with/)
- [Phase 1/2 Clinical Trial Evaluating 4d-310 In Adults With Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 21-42 Months of Follow Up (Poster)](https://4dmoleculartherapeutics.com/publications/phase-1-2-clinical-trial-evaluating-4d-310-in-adults-with-fabry-disease-cardiomyopathy-interim-analysis-of-cardiac-and-safety-outcomes-in-patients-with-21-42-months-of-follow-up-poster/)
- [Phase 1/2 Clinical Trial Evaluating 4d-310 In Adults With Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 21-42 Months of Follow Up](https://4dmoleculartherapeutics.com/publications/phase-1-2-clinical-trial-evaluating-4d-310-in-adults-with-fabry-disease-cardiomyopathy-interim-analysis-of-cardiac-and-safety-outcomes-in-patients-with-21-42-months-of-follow-up/)
- [Non-clinical Evaluation of 4D-310 in Combination With Rituximab/Sirolimus: A Translational Study to Support Adoption of a Novel Prophylactic Immunomodulation Regimen in Clinical Trials in Adults with Fabry Disease](https://4dmoleculartherapeutics.com/publications/non-clinical-evaluation-of-4d-310-in-combination-with-rituximab-sirolimus-a-translational-study-to-support-adoption-of-a-novel-prophylactic-immunomodulation-regimen-in-clinical-trials-in-adults-with-2/)
- [Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies](https://4dmoleculartherapeutics.com/publications/design-and-characterization-of-a-novel-intravitreal-dual-transgene-genetic-medicine-for-neovascular-retinopathies/)
- [Extended Follow-Up in the PRISM Clinical Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular Degeneration](https://4dmoleculartherapeutics.com/publications/extended-follow-up-in-the-prism-clinical-trial-evaluating-4d-150-in-adults-with-neovascular-age-related-macular-degeneration/)
- [Interim Results from the PRISM Phase 1/2 Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Neovascular Age-Related Macular Degeneration](https://4dmoleculartherapeutics.com/publications/interim-results-from-the-prism-phase-1-2-clinical-trial-evaluating-intravitreal-4d-150-in-adults-with-neovascular-age-related-macular-degeneration/)
- [Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults With Neovascular Age-related Macular Degeneration](https://4dmoleculartherapeutics.com/publications/phase-2-population-extension-cohort-in-the-prism-trial-evaluating-4d-150-in-adults-with-neovascular-age-related-macular-degeneration/)
- [24-week Results from the Randomized Phase 2 Dose Expansion Stage of the PRISM Trial Evaluating 4D-150 in High Need nAMD Patients: Injection-free Patient Analyses](https://4dmoleculartherapeutics.com/publications/24-week-results-from-the-randomized-phase-2-dose-expansion-stage-of-the-prism-trial-evaluating-4d-150-in-high-need-namd-patients-injection-free-patient-analyses/)
- [<em>CFTR</em> Transgene Expression in Airway Epithelial Cells Following Aerosolized Administration of the AAV-based Gene Therapy 4D-710 to Adults with Cystic Fibrosis Lung Disease](https://4dmoleculartherapeutics.com/publications/cftr-transgene-expression-in-airway-epithelial-cells-following-aerosolized-administration-of-the-aav-based-gene-therapy-4d-710-to-adults-with-cystic-fibrosis-lung-disease/)
- [Interim Results from the PRISM Randomized Phase 2 Dose Expansion Trial Evaluating 4D-150 in High Anti-VEGF Need Individuals with Neovascular (Wet) Age-Related Macular Degeneration](https://4dmoleculartherapeutics.com/publications/interim-results-from-the-prism-randomized-phase-2-dose-expansion-trial-evaluating-4d-150-in-high-anti-vegf-need-individuals-with-neovascular-wet-age-related-macular-degeneration/)
- [Preclinical Characterization of 4D-175, a Novel AAV-Based Investigational Intravitreal Gene Therapy for Geographic Atrophy](https://4dmoleculartherapeutics.com/publications/preclinical-characterization-of-4d-175-a-novel-aav-based-investigational-intravitreal-gene-therapy-for-geographic-atrophy/)
- [First Interim Results (24 weeks) for the Randomized Phase 2 Dose Expansion Stage of the PRISM Clinical Trial of 4D-150 in High Need Patients with nAMD](https://4dmoleculartherapeutics.com/publications/first-interim-results-24-weeks-for-the-randomized-phase-2-dose-expansion-stage-of-the-prism-clinical-trial-of-4d-150-in-high-need-patients-with-namd/)
- [Phase 1/2 Clinical Trial Evaluating 4D-310 in Adults with Fabry Disease Cardiomyopathy: Interim Analysis of Cardiac and Safety Outcomes in Patients with 12–33 Months of Follow-up](https://4dmoleculartherapeutics.com/publications/phase-1-2-clinical-trial-evaluating-4d-310-in-adults-with-fabry-disease-cardiomyopathy-interim-analysis-of-cardiac-and-safety-outcomes-in-patients-with-12-33-months-of-follow-up/)
- [Targeting the Complement Pathway with AAV-Based Gene Therapy for Geographic Atrophy](https://4dmoleculartherapeutics.com/publications/targeting-the-complement-pathway-with-aav-based-gene-therapy-for-geographic-atrophy/)
- [Interim Results of the Phase 1/2 PRISM Trial Evaluating 4D-150, a Dual-Transgene Intravitreal Genetic Medicine for Neovascular (Wet) Age-Related Macular Degeneration](https://4dmoleculartherapeutics.com/publications/interim-results-of-the-phase-1-2-prism-trial-evaluating-4d-150-a-dual-transgene-intravitreal-genetic-medicine-for-neovascular-wet-age-related-macular-degeneration/)
- [AAV-Mediated Gene Therapy for Cystic Fibrosis (4D 710)](https://4dmoleculartherapeutics.com/publications/aav-mediated-gene-therapy-for-cystic-fibrosis-4d-710/)
- [A Phase 1/2 Clinical Trial Evaluating 4D-150, a Dual-transgene Intravitreal Gene Therapy in Patients with Wet Age-Related Macular Degeneration: Interim Results](https://4dmoleculartherapeutics.com/publications/a-phase-1-2-clinical-trial-evaluating-4d-150-a-dual-transgene-intravitreal-gene-therapy-in-patients-with-wet-age-related-macular-degeneration-interim-results/)
- [Plenary 2: Novel CF Therapeutics & Clinical Trial Strategy to Accelerate Our Mission](https://4dmoleculartherapeutics.com/publications/plenary-2-novel-cf-therapeutics-clinical-trial-strategy-to-accelerate-our-mission/)
- [Update on AAV-mediated CFTR gene delivery programme (4D-710)](https://4dmoleculartherapeutics.com/publications/update-on-aav-mediated-cftr-gene-delivery-programme-4d-710/)
- [A Multi-Mechanistic Anti-Angiogenic AAV Gene Therapy Product Candidate, 4D-150, for the Treatment of Wet Age-Related Macular Degeneration (Wet AMD) and Diabetic Macular Edema (DME): Intravitreal Biodistribution, Transgene Expression, Safety and Efficacy in Non-Human Primates](https://4dmoleculartherapeutics.com/publications/a-multi-mechanistic-anti-angiogenic-aav-gene-therapy-product-candidate-4d-150-for-the-treatment-of-wet-age-related-macular-degeneration-wet-amd-and-diabetic-macular-edema-dme-intravitreal-biodi/)
- [4D-C102, a Novel Muscle-Tropic AAV Variant Demonstrates Superior Gene Delivery in Cardiac and Skeletal Muscle Tissues Versus Wild-Type AAV in Human Cells and Non-Human Primates](https://4dmoleculartherapeutics.com/publications/4d-c102-a-novel-muscle-tropic-aav-variant-demonstrates-superior-gene-delivery-in-cardiac-and-skeletal-muscle-tissues-versus-wild-type-aav-in-human-cells-and-non-human-primates/)
- [An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adult Males with Fabry Disease](https://4dmoleculartherapeutics.com/publications/an-open-label-phase-1-2-trial-of-gene-therapy-4d-310-in-adult-males-with-fabry-disease/)
- [A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non-Human Primates](https://4dmoleculartherapeutics.com/publications/a-targeted-aav-gene-therapy-product-candidate-4d-310-for-the-treatment-of-fabry-disease-intravenous-biodistribution-transgene-expression-safety-in-non-human-primates/)
- [Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease](https://4dmoleculartherapeutics.com/publications/identification-and-characterization-of-a-novel-aav-capsid-product-for-the-treatment-of-cystic-fibrosis-lung-disease/)
- [Directed Evolution of AAV Targeting Lung Epithelia Using Aerosol Delivery Identifies 4D-A101, a Variant Demonstrating Robust Gene Delivery in Non-Human Primates](https://4dmoleculartherapeutics.com/publications/directed-evolution-of-aav-targeting-lung-epithelia-using-aerosol-delivery-identifies-4d-a101-a-variant-demonstrating-robust-gene-delivery-in-non-human-primates/)
- [In Vitro Fabry Disease Correction in Patient iPSC-Derived Cardiomyocytes and Endothelial Cells Using an Evolved and Optimized AAV Gene Therapeutic (4D-310)](https://4dmoleculartherapeutics.com/publications/in-vitro-fabry-disease-correction-in-patient-ipsc-derived-cardiomyocytes-and-endothelial-cells-using-an-evolved-and-optimized-aav-gene-therapeutic-4d-310/)
- [Highly-Evolved Novel AAV Gene Therapy Directly Addresses Fabry Disease Pathology In Vivo by Cell Autonomous Expression in the Heart and Other Target Organs](https://4dmoleculartherapeutics.com/publications/highly-evolved-novel-aav-gene-therapy-directly-addresses-fabry-disease-pathology-in-vivo-by-cell-autonomous-expression-in-the-heart-and-other-target-organs/)

## Categories

- [Scientific Presentation](https://4dmoleculartherapeutics.com/category/scientific-presentation/)
- [News & Updates](https://4dmoleculartherapeutics.com/category/news-updates/)
- [Leadership in the News](https://4dmoleculartherapeutics.com/category/leadership-in-the-news/)

## Portfolio Categories

- [Team](https://4dmoleculartherapeutics.com/team_entries/team/)
- [Leadership](https://4dmoleculartherapeutics.com/team_entries/leadership/)
- [Board](https://4dmoleculartherapeutics.com/team_entries/board/)
- [SAB](https://4dmoleculartherapeutics.com/team_entries/sab/)
- [OAB](https://4dmoleculartherapeutics.com/team_entries/oab/)
- [LAB](https://4dmoleculartherapeutics.com/team_entries/lab/)
~~~

## llms-full

Not found.